Nu-Med Plus, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 15, 2021 at 05:26 pm EST
Share
Nu-Med Plus, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 0.118366 million compared to USD 0.453824 million a year ago.
For the nine months, net loss was USD 0.71772 million compared to USD 1.52 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.03 a year ago.
Nu-Med Plus, Inc. is a medical device company, which is principally engaged in the designing, development, enhancement and commercialization of later-stage medical devices. The Company is focused on the creation of a nitric oxide generating formulation, a hospital bedside nitric oxide (NO) delivery system, a clinical unit for use in medical clinics and rehabilitation centers and a mobile rechargeable device to deliver nitric oxide gas to offer solutions to hospitals, health systems and the medical community throughout the world. Hospital NO Unit delivers a continuous intra-breath concentration of therapeutic NO to patients who are on a ventilator in a hospital setting. Clinical Delivery System is a simplified version of the hospital unit. Portable Delivery System delivers high purity NO to the patient at prescribed intervals for 24 hours per day at controlled doses by means of a nasal cannula or a face mask. Reagent Delivery provides a range of concentrations and flow rates of NO.
NU-MED PLUS, INC. 
